OSI Pharmaceuticals

Quick facts

Phase 3 pipeline

• Combination carboplatin and paclitaxel · Oncology
  This combination uses carboplatin to cross-link DNA and paclitaxel to stabilize microtubules, together inducing cancer cell death through complementary cytotoxic mechanisms.

Phase 2 pipeline

• OSI 7904L

Phase 1 pipeline

• Tarceva, erlotinib, OSI-774

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• OSI Pharmaceuticals portfolio CI brief
• OSI Pharmaceuticals pipeline updates RSS